Exhibit 99.1



FOR IMMEDIATE RELEASE

Contact:  Adam C. Derbyshire            Mike Freeman
          Vice President and            Director, Investor Relations and
          Chief Financial Officer       Corporate Communications
          919-862-1000                  919-862-1000


                    SALIX PHARMACEUTICALS ANNOUNCES SECOND
                   QUARTER 2001 CONFERENCE CALL AND WEBCAST

RALEIGH, NC, July 30, 2001 - Salix Pharmaceuticals, Ltd.  (Nasdaq:SLXP) today
announced that the Company will report second quarter 2001 financial results
before the market opens on Wednesday, August 1, 2001.

The Company will host a conference call at 8:30 a.m. EDT on August 1.
Interested parties may access the conference call by way of webcast or
telephone.  The live webcast will be available at http://www.salixpharm.com.  To
                                                  -------------------------
access the live webcast, log on to the Company's web site at the address listed
above and go to the investor information section.  The webcast will be archived
on the Company's web site through August 8.

The telephone numbers to access the conference call are (800) 310-1961 (U.S. and
Canada) or (719) 457-2692 (international.)   A replay of the call will be
available from 1:00 p.m. EDT, August 1 through August 8.   The telephone numbers
to access the replay of the call are (888) 203-1112 (U.S. and Canada) or (719)
457-0820 (international.)  The access code for the replay is 788979.

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops
and markets prescription pharmaceutical products for the treatment of
gastrointestinal diseases.  Salix's strategy is to in-license proprietary
therapeutic drugs which have an existing database of positive, late-stage
clinical data; complete the development and regulatory submission of these
products;


and market them through the Company's gastroenterology specialty sales force.
Salix's lead product is COLAZAL(TM), an anti-inflammatory drug approved for the
treatment of mildly to moderately active ulcerative colitis. The Company
launched the product in the U.S. through its specialty sales force in January
2001. Salix's follow-on product candidate is rifaximin, currently in development
for the potential treatment of infections of the lower gastrointestinal tract.
The Company currently intends to submit an NDA for rifaximin for the treatment
of infectious diarrhea to the U.S. FDA in late 2001. Salix trades on the Nasdaq
National Market under the ticker symbol "SLXP."

For more information please contact the Company at 919-862-1000 or visit our web
site at www.salixpharm.com.
        ------------------

                                      ###

     Please Note: This press release contains forward-looking statements
     regarding future events. These statements are just predictions and are
     subject to risks and uncertainties that could cause the actual events or
     results to differ materially. These risks and uncertainties include the
     uncertainty of market acceptance of COLAZAL and rifaximin, our limited
     sales and marketing experience, risks of clinical trials and regulatory
     review, and the need to acquire new products. The reader is referred to the
     documents that the Company files from time to time with the Securities and
     Exchange Commission.